Ajanta Pharma Ltd posted a consolidated Q2 revenue of ₹13.54 billion and net profit of ₹2.6 billion, while declaring a ₹28 per share interim dividend. The strong performance and shareholder return highlight the company’s operational strength and growth momentum .
Ajanta Pharma Ltd announced strong consolidated results for the September quarter, with revenue from operations reaching ₹13.54 billion and a consolidated net profit of ₹2.6 billion. The company also declared an interim dividend of ₹28 per share, reflecting confidence in its robust financial position.
Revenue and Profit Performance
-
Consolidated revenue stood at ₹13.54 billion, showcasing consistent growth amid challenging market dynamics .
-
Net profit of ₹2.6 billion underscores the company’s efficient cost structure and sustained demand across portfolios.
Dividend Declaration
Ajanta Pharma declared an attractive interim dividend of ₹28 per share, signaling strong cash flows and shareholder value commitment.
Operational Strength
-
The company continues to expand its footprint in specialty pharmaceuticals and emerging markets, driving growth.
-
Product innovation and enhanced manufacturing capabilities remain key growth drivers.
Outlook and Strategic Focus
-
Ajanta Pharma is well-positioned to leverage new product launches and market expansion plans.
-
The company emphasizes sustained profitability through strategic investments and operational efficiency.
This quarter’s results and dividend announcement reinforce Ajanta Pharma’s reputation as a resilient and shareholder-focused pharmaceutical leader.
Sources: Moneycontrol, Economic Times, company disclosures.